2024
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchProstate cancerPatientsMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original Research‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.Peer-Reviewed Original ResearchProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerActive surveillanceActive surveillance of prostate cancerGleason Grade Group 1Surveillance of prostate cancerIntermediate-risk prostate cancerMonitoring of prostate cancerMRI-ultrasound fusion biopsyGrade group 1Monitoring prostate cancerGroup 2 tumorsMagnetic resonance imaging scansFusion biopsyLongitudinal follow-upProstate biopsyFollow-upProstateSemi-structured interviews of patientsMRI useQualitative studyGroup 1Interviews of patientsPatientsUpdated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C, Cheng S. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal Of Clinical Oncology 2024, 42: 1943-1952. PMID: 38507655, DOI: 10.1200/jco.23.01604.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProton beam therapyGU toxicityProstate cancerGI toxicityBenefits of proton beam therapyIntensity-modulated radiation therapy patientsPBT patientsLocalized prostate cancerTreatment-related toxicityComparison of GIStatistically significant differenceRadiation therapyBeam therapySEER-MedicareToxicity of protonProcedure codesComparative effectiveness studiesObservational studyPatientsSignificant differenceCancerMonthsComparing GIProstateTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries
2023
Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer
Leapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGrade group 2 prostate cancerGleason Grade Group 1Risk prostate cancerGrade group 1Prostate cancer riskProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsGenomic test resultsConclusions PatientsInitial biopsyPhysician recommendationPatient knowledgePatient counsellingConventional content analysisCancer managementExpression testRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseasePD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER
Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.Peer-Reviewed Original ResearchPatient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGleason Grade Group 1Risk prostate cancerGrade group 1Routine clinical careProstate cancer riskGroup 2 tumorsProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsRace/ethnicityInitial biopsyPatient knowledgeMean agePatient counselingCancer managementClinical careExpression test“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance.
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D, Leapman M. “It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. Journal Of Clinical Oncology 2023, 41: 334-334. DOI: 10.1200/jco.2023.41.6_suppl.334.Peer-Reviewed Original ResearchActive surveillanceProstate cancerProstate MRIPatient experienceGleason Grade Group 1Prostate cancer active surveillanceIntermediate-risk prostate cancerRisk prostate cancerGrade group 1Group 2 tumorsMRI-ultrasound fusion biopsyMean sample ageHispanics/LatinosInitial diagnosisFusion biopsyProstate biopsyConventional content analysisPatient's perspectiveClinical careGroup 1MRI resultsMRI scansProviders' explanationsCancerPatientsUse of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
2021
Mediators of racial disparity in the use of prostate MRI.
Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.Peer-Reviewed Original ResearchProstate cancerRacial disparitiesProstate MRIMRI useArea-level measuresObserved racial disparitiesEligible patientsPathologic factorsDual eligibilityWhite patientsBlack patientsSEER regionMedicare databaseCancer careSix-month periodPatientsSociodemographic factorsCancerMRIZip codesOlder AmericansMediatorsDiagnostic toolObserved disparitiesHigh-poverty areas
2020
Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapyMP23-17 ASSOCIATIONS OF REGIONAL-LEVEL ADOPTION OF PROSTATE MRI AND GENOMIC TESTING AND OBSERVATION FOR PROSTATE CANCER
Leapman* M, Wang R, Ma X, Gross C. MP23-17 ASSOCIATIONS OF REGIONAL-LEVEL ADOPTION OF PROSTATE MRI AND GENOMIC TESTING AND OBSERVATION FOR PROSTATE CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000856.017.Peer-Reviewed Original Research
2019
Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.
Yang D, Makarov D, Gross C, Yu J. Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening. Journal Of Clinical Oncology 2019, 37: 1567-1567. DOI: 10.1200/jco.2019.37.15_suppl.1567.Peer-Reviewed Original ResearchProstate cancer incidenceHealth service areasMetastatic prostate cancerMetastatic prostate cancer incidenceMetastatic diseaseCancer incidenceProstate cancerLocalized diseasePopulation-weighted linear regressionMen 70 yearsEnd Results (SEER) databaseHealth Service regionResults databaseIncidence rateHospital careMetastatic incidenceIncidenceDiseaseCancerLate increasePSALinear regressionMenTemporal relationshipSurveillance
2018
MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT
Leapman M, Wang R, Park H, Yu J, Gross C, Ma X. MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT. Journal Of Urology 2018, 199: e707. DOI: 10.1016/j.juro.2018.02.1679.Peer-Reviewed Original ResearchMP12-15 NATIONAL TRENDS IN THE MANAGEMENT OF LOCALIZED PROSTATE CANCER FROM A POPULATION-BASED COHORT OF PRIVATELY INSURED PATIENTS
Kim S, Karnes J, Bukavina L, Van Houten H, Gross C, Mwangi R, Shah N. MP12-15 NATIONAL TRENDS IN THE MANAGEMENT OF LOCALIZED PROSTATE CANCER FROM A POPULATION-BASED COHORT OF PRIVATELY INSURED PATIENTS. Journal Of Urology 2018, 199: e141-e142. DOI: 10.1016/j.juro.2018.02.402.Peer-Reviewed Original Research
2017
PD09-02 RACIAL VARIATION IN THE REFUSAL OF INITIAL TREATMENT PLAN AMONG MEN DIAGNOSED WITH LOCALIZED PROSTATE CANCER
Scarberry K, Scarberry K, Abouassaly R, Gonzalez C, Gross C, Shah N, Meropol N, Psutka S, Prasad S, Bukavina L, Kim S. PD09-02 RACIAL VARIATION IN THE REFUSAL OF INITIAL TREATMENT PLAN AMONG MEN DIAGNOSED WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2017, 197: e194. DOI: 10.1016/j.juro.2017.02.552.Peer-Reviewed Original Research